## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.8% below STRENGTH zone (4.0-10.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($214.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Danaher Corporation $DHR Shares Sold by State Street Corp**
- Source: MarketBeat | 20251209T132720 | Somewhat-Bullish | Relevance: 99%
-  State Street Corp reduced its stake in Danaher Corporation (NYSE:DHR) by 0.6% in the second quarter, selling 164,456 shares and retaining 27,299,515 shares valued at $5.4 billion. Other institutional investors also adjusted their positions, with insider selling by Director Teri List and SVP Brian W. Ellis totaling over $5.5 million in the last ninety days. Analysts have a "Moderate Buy" rating on DHR, with a consensus price target of $246.79.

**2. Leica Biosystems Expands Clinical Digital Pathology Portfolio with Multiple Launches at DPAI 2025**
- Source: PR Newswire | 20251209T080000 | Bullish | Relevance: 99%
-  Leica Biosystems has expanded its clinical digital pathology portfolio by launching the Aperio GT 180 DX scanner, Aperio CS5 DX scanner, and Aperio iQC DX software at the Digital Pathology and AI (DPAI) Congress in London. These new solutions aim to streamline slide quality control, improve efficiency for mid-volume laboratories, and provide versatile scanning options. The company emphasizes its commitment to delivering innovative solutions for faster, accurate diagnostics and improved patient outcomes.

**3. Danaher Corporation $DHR Shares Purchased by Guggenheim Capital LLC**
- Source: MarketBeat | 20251207T110056 | Somewhat-Bullish | Relevance: 98%
-  Guggenheim Capital LLC increased its stake in Danaher Corporation (NYSE:DHR) by 25.3% in the second quarter, bringing its total holdings to 34,066 shares valued at $6,729,000. Several other institutional investors also adjusted their positions in DHR. Insider activity included sales by SVP Brian W. Ellis and Director Teri List, while analysts have a "Moderate Buy" consensus rating with an average target price of $245.75 for Danaher.

**4. Ossiam Has $28.59 Million Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T115110 | Bullish | Relevance: 98%
-  Ossiam significantly increased its stake in Danaher Corporation by 716.7% in Q2, bringing its total holdings to 144,744 shares valued at $28.59 million. Despite recent insider sales totaling over $6.6 million, Wall Street analysts maintain a "Moderate Buy" consensus rating for Danaher, with an average price target of $245.75, following its beat on quarterly EPS expectations. The company also announced a quarterly dividend of $0.32 per share, yielding 0.6% annually.

**5. California Public Employees Retirement System Has $270.06 Million Position in Danaher Corporation $DHR**
- Source: MarketBeat | 20251207T101656 | Somewhat-Bullish | Relevance: 98%
-  California Public Employees Retirement System (CalPERS) recently reduced its stake in Danaher Corporation (NYSE:DHR) by 1.8% in Q2, now holding 1,367,132 shares valued at $270.06 million. Despite this, institutional investors and hedge funds own 79.05% of the stock. Insiders have also sold shares totaling over $6.6 million recently, and analysts currently rate Danaher as a "Moderate Buy" with an average price target of $245.75.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $76M sold (10 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Forward P/E 26.7x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $160.7B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 26.7 |
| Current P/E | 29.1 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.8% to -1.8% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.8pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.51), momentum weakening. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.76% (CS: 42) | Neutral |
| RSI_14 | 54.7 | Neutral |
| MACD Histogram | -0.51 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.105x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $224.48
- **Stop Loss:** $214.86 (4.3% risk)
- **Target:** $234.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $11,448.48
- **Portfolio %:** 11.45%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*